A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304

Phase 2 Terminated 116 enrolled TG Therapeutics, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to provide the opportunity to the participants who progressed on treatment arm previously in the study UTX-TGR-304 (NCT02612311) to receive ublituximab (TG-1101) treatment in combination with umbralisib (TGR-1202).

Timeline

Start: 2016-01-07
Primary completion: 2022-05-26
Completion: 2022-07-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ublituximab	Monoclonal antibody	900 mg	Intravenous
Subject	Umbralisib	Small molecule	800 mg	Oral

A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304

Summary

Timeline

Drugs

Indications